{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:39:57Z","timestamp":1791808797848,"version":"4.3.4"},"reference-count":136,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016039","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:51:42Z","timestamp":1743303102000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Nikki","family":"Jahnke","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, Medicine & Health Sciences; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases; Hospital for Sick Children; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; The Hospital for Sick Children; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, Medicine & Health Sciences; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R","family":"Hambleton","sequence":"additional","affiliation":[{"name":"George Alleyne Chronic Disease Research Centre; The University of the West Indies; Bridgetown Barbados"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Scharf","sequence":"additional","affiliation":[{"name":"Parent of a child with cystic fibrosis; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p. (Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD016039-BIB0002|cit2","unstructured":"Cystic Fibrosis Foundation Patient registry report 2021 https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"00724","DOI":"10.1183\/23120541.00724-2021","article-title":"CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011\u20132018","volume":"8","author":"Ricotta","year":"2022","journal-title":"European Respiratory Journal Open Research"},{"key":"10.1002\/14651858.CD016039-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Wiesel V Aviram M Mei-Zahav M Dotan M Prais D Cohen-Cymberknoh M Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study Journal of Cystic Fibrosis 2023 23 1 41 9 10.1016\/j.jcf.2023.05.003","DOI":"10.1016\/j.jcf.2023.05.003"},{"key":"10.1002\/14651858.CD016039-BIB0005|cit5","volume-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","author":"Bennett","year":"2019"},{"issue":"3","key":"10.1002\/14651858.CD016039-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AEM.67.3.1225-1231.2001","article-title":"Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare and other Mycobacteria in drinking water distribution systems","volume":"67","author":"Falkinham","year":"2001","journal-title":"Applied and Environmental Microbiology"},{"key":"10.1002\/14651858.CD016039-BIB0007|cit7","unstructured":"Annual data report https:\/\/archive.cysticfibrosis.ca\/uploads\/2021-Annual-Data-Report-WEB-AODA.pdf"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"00336","DOI":"10.1183\/23120541.00336-2022","article-title":"Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis","volume":"9","author":"Prieto","year":"2023","journal-title":"European Respiratory Journal Open Research"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12879-023-08468-6","article-title":"Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019)","volume":"23","author":"Marshall","year":"2023","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD016039-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijid.2023.01.032","article-title":"Epidemiological trends in nontuberculous mycobacterial infection among people with cystic fibrosis in Germany","volume":"129","author":"Steindor","year":"2023","journal-title":"International Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"e00069","DOI":"10.1128\/CMR.00069-18","article-title":"Cutaneous mycobacterial infections","volume":"32","author":"Franco-Paredes","year":"2018","journal-title":"Clinical Microbiology Reviews"},{"issue":"8","key":"10.1002\/14651858.CD016039-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10096-011-1510-9","article-title":"The use of a two-gene sequencing approach to accurately distinguish between the species within the Mycobacterium abscessus complex and Mycobacterium chelonae","volume":"31","author":"Blauwendraat","year":"2012","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD016039-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subs. abscessus, Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"International Journal of Systematic and Evolutionary Microbiology"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1164\/rccm.200207-678OC","article-title":"Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease","volume":"167","author":"Olivier","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01257-09","article-title":"Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France","volume":"47","author":"Roux","year":"2009","journal-title":"Journal of Clinical Microbiology"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jcf.2019.07.007","article-title":"Distribution and outcomes of infection of Mycobacterium avium complex species in cystic fibrosis","volume":"19","author":"Azar","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2012.06.009","article-title":"Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations","volume":"12","author":"Catherinot","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ppul.20222","article-title":"Nontuberculous mycobacterial infection in young children with cystic fibrosis","volume":"40","author":"Esther","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD016039-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1128\/JCM.43.7.3467-3470.2005","article-title":"Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis","volume":"43","author":"Pierre-Audigier","year":"2005","journal-title":"Journal of Clinical Microbiology"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcf.2014.08.002","article-title":"Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia","volume":"14","author":"Qvist","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD016039-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ppul.21106","article-title":"Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors","volume":"44","author":"Radhakrishnan","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/jcm.31.4.861-864.1993","article-title":"Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis","volume":"31","author":"Whittier","year":"1993","journal-title":"Journal of Clinical Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0023|cit23","first-page":"630","article-title":"Epidemiology of infection by nontuberculous mycobacteria. V. Numbers in eastern United States soils and correlation with soil characteristics","volume":"130","author":"Brooks","year":"1984","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD016039-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-11-113","article-title":"Mycobacterial infections in a large Virginia hospital, 2001\u20132009","volume":"11","author":"Satyanarayana","year":"2011","journal-title":"BMC Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"e0259964","DOI":"10.1371\/journal.pone.0259964","article-title":"Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida","volume":"16","author":"Foote","year":"2021","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jhin.2016.04.015","article-title":"Investigation of Mycobacterium abscessus outbreak among cystic fibrosis patients, Hawaii 2012","volume":"94","author":"Johnston","year":"2016","journal-title":"Journal of Hospital Infection"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esserman","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1164\/ajrccm.185.2.231","article-title":"Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center","volume":"185","author":"Aitken","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6313","key":"10.1002\/14651858.CD016039-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1126\/science.aaf8156","article-title":"Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium","volume":"354","author":"Bryant","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12879-018-3200-z","article-title":"Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis","volume":"18","author":"Eikani","year":"2018","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/ajrccm\/147.5.1271","article-title":"Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients","volume":"147","author":"Griffith","year":"1993","journal-title":"American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/322633","article-title":"Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid","volume":"33","author":"Maniu","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD016039-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.201111-2005OC","article-title":"Macrolide treatment for Mycobacterium abscessus and M. massiliense infection and inducible resistance","volume":"186","author":"Choi","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2014.07.004","article-title":"Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients","volume":"14","author":"Roux","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/138161212799315939","article-title":"New treatments for emerging cystic fibrosis pathogens other than Pseudomonas","volume":"18","author":"Waters","year":"2012","journal-title":"Current Pharmaceutical Design"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006454-199704000-00004","article-title":"Mycobacterial lung disease in cystic fibrosis: a prospective study","volume":"16","author":"Fauroux","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"7","key":"10.1002\/14651858.CD016039-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010004","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","author":"Waters","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010004.pub2","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","author":"Waters","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010004.pub3","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","author":"Waters","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD016039-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010004.pub4","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","author":"Waters","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010004.pub5","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","author":"Waters","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016039-BIB0045|cit45","unstructured":"Jahnke N Smith S Scharf N Ratjen F Waters V Hambleton I Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=485297"},{"key":"10.1002\/14651858.CD016039-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2017.09.010","article-title":"Big-5 quasi-experimental designs","volume":"89","author":"Tugwell","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016039-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jclinepi.2017.02.016","article-title":"Quasi-experimental study designs series-paper 5: a checklist for classifying studies evaluating the effects on health interventions-a taxonomy without labels","volume":"89","author":"Reeves","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016039-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jclinepi.2021.11.026","article-title":"GRADE guidance 24 optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines","volume":"142","author":"Cuello-Garcia","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD016039-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax.55.11.946","article-title":"Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis","volume":"55","author":"Gee","year":"2000","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD016039-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016039-BIB0052|cit52","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD016039-BIB0053|cit53","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016039-BIB0054|cit54","first-page":"i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016039-BIB0055|cit55","unstructured":"Sterne JA Hern\u00e1n MA McAleenan A Reeves BC Higgins JP Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"10","key":"10.1002\/14651858.CD016039-BIB0056|cit56","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evidence Synthesis"},{"key":"10.1002\/14651858.CD016039-BIB0057|cit57","unstructured":"Deeks JJ Higgins JP Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 10: Analysing data and undertaking meta-analyses. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook of Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"24","key":"10.1002\/14651858.CD016039-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016039-BIB0059|cit59","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijmy.ijmy_3_20","article-title":"Outcomes of pulmonary Mycobacterium abscessus infection","volume":"9","author":"Flight","year":"2020","journal-title":"International Journal of Mycobacteriology"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0062|cit62","first-page":"A4126","article-title":"A randomized, double-blind, placebo-controlled study of liposomal Amikacin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung disease","volume":"189","author":"Olivier","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0063|cit63","first-page":"A6295","article-title":"Efficacy of liposomal amikacin for inhalation (LAI) in achieving nontuberculous mycobacteria (NTM) culture negativity in patients whose lung infection is refractory to guideline-based therapy","volume":"191","author":"Biller","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD016039-BIB0064|cit64","unstructured":"Liposomal amikacin for inhalation (LAI) for nontuberculous mycobacteria clinicaltrials.gov\/show\/NCT01315236"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0065|cit65","first-page":"A6294","article-title":"Subgroup analyses of baseline demographics and efficacy in patients with refractory nontuberculous mycobacteria (NTM) lung infection treated with liposomal amikacin for inhalation (LAI)","volume":"191","author":"Winthrop","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0067|cit67","first-page":"A1984","article-title":"Six-minute walk test (6MWT) performance in adult patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)","volume":"197","author":"Winthrop","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0068|cit68","first-page":"A6296","article-title":"Analysis of functional exercise capacity (via the six-minute walk test [6MWT]) and culture negativity in patients with nontuberculous mycobacteria (NTM) lung infection refractory to guideline-based therapy treated with liposomal amikacin for inhalation (LAI)","volume":"191","author":"Ruoss","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"SUPPL. 38","key":"10.1002\/14651858.CD016039-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ppul.23108","article-title":"Randomized, double-blind, placebo-controlled, open-label study of liposomal amikacin for inhalation (LAI) in patients with recalcitrant nontuberculous mycobacterial lung disease (NTM-LD)","volume":"49","author":"Olivier","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD016039-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1569-1993(15)30009-6","article-title":"Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD)","volume":"14","author":"Olivier","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1513\/AnnalsATS.201508-529OC","article-title":"Improvement in quality of life after therapy for mycobacterium abscessus group lung infection a prospective cohort study","volume":"13","author":"Czaja","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jcf.2017.04.013","article-title":"Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients","volume":"16","author":"DaCosta","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Supplement 45","key":"10.1002\/14651858.CD016039-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ppul.23576","article-title":"Outcomes of mycobacterium abscessus treatment in patients with cystic fibrosis","volume":"51","author":"Esther","year":"2016","journal-title":"Pediatric Pulmonology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD016039-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1569-1993(16)30344-7","article-title":"Clinical evaluation of cystic fibrosis patients with Mycobacterium abscessus infection","volume":"15","author":"Emiralioglu","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"2003636","DOI":"10.1183\/13993003.03636-2020","article-title":"Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis","volume":"57","author":"Hughes","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD016039-BIB0076|cit76","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016039-BIB0077|cit77","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2023"},{"key":"10.1002\/14651858.CD016039-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2190\/986L-LHQ6-2VTE-YRRN","article-title":"The concepts and principles of equity and health","volume":"22","author":"Whitehead","year":"1992","journal-title":"International Journal of Health Services"},{"key":"10.1002\/14651858.CD016039-BIB0079|cit79","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016039-BIB0080|cit80","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016039-BIB0081|cit81","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"8","key":"10.1002\/14651858.CD016039-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/08035250310004388","article-title":"Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis","volume":"92","author":"Forslow","year":"2003","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD016039-BIB0083|cit83","unstructured":"IV gallium study for patients with cystic fibrosis who have NTM (ABATE Study) (ABATE) www.clinicaltrials.gov\/ct2\/show\/NCT04294043"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jcf.2019.07.007","article-title":"Distribution and outcomes of infection of Mycobacterium avium complex species in cystic fibrosis","volume":"19","author":"Azar","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0085|cit85","article-title":"Nitric oxide inhalations in CF patients infected with mycobacterium abscessus complex: a prospective, open-labeled, multi-center pilot study","volume":"197","author":"Bentur","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"SUPPL 2","key":"10.1002\/14651858.CD016039-BIB0086|cit86","first-page":"207","article-title":"A proof-of-concept study of inhaled nitric oxide for adults with pulmonary nontuberculous mycobacterial infection","volume":"55","author":"Garcia","year":"2020","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD016039-BIB0087|cit87","unstructured":"A prospective standardized assessment of people with cystic fibrosis and non-tuberculosis Mycobacteria pulmonary disease undergoing treatment with mycobacteriophage (POSTSTAMP) clinicaltrials.gov\/study\/NCT06262282"},{"issue":"4 Supplement","key":"10.1002\/14651858.CD016039-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"A470","DOI":"10.1016\/j.chest.2022.08.361","article-title":"Home-based treatment of nontuberculous mycobacteria pulmonary disease via a novel nitric oxide generator and delivery system","volume":"162","author":"Thomson","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate nitric oxide adjuvant treatment of persistent mycobacterium infection in cystic fibrosis patients","volume":"37","author":"Yaacoby-Bianu","year":"2018","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD016039-BIB0090|cit90","first-page":"A5915","article-title":"Randomized phase 3 trial of amikacin liposome inhalation suspension (ALIS) for treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC) in adult patients","volume":"197","author":"Griffith","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD016039-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"e0082423","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jpc.14427","article-title":"Pulmonary Mycobacterium abscessus complex in children with cystic fibrosis: A practical management guideline","volume":"55","author":"Andrew","year":"2019","journal-title":"Journal of Paediatrics and Child Health"},{"key":"10.1002\/14651858.CD016039-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71 Suppl 1","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD016039-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1002\/ppul.24939","article-title":"Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis","volume":"56 Suppl 1","author":"Laudone","year":"2021","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ccm.2022.06.008","article-title":"Novel approaches to multidrug-resistant infections in cystic fibrosis","volume":"43","author":"Murray","year":"2022","journal-title":"Clinics in Chest Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.idc.2023.12.002","article-title":"Novel approaches to multidrug-resistant infections in cystic fibrosis","volume":"38","author":"Murray","year":"2024","journal-title":"Infectious Disease Clinics of North America"},{"key":"10.1002\/14651858.CD016039-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/ppul.24522","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54 Suppl 3","author":"Saiman","year":"2019","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD016039-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.arbres.2023.07.021","article-title":"Clinical and treatment outcome differences between the most common nontuberculous mycobacteria (NTM) in the Basque Country","volume":"59","author":"Tabernero Huguet","year":"2023","journal-title":"Archivos de Bronconeumologia"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1183\/09031936.00065612","article-title":"Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients","volume":"41","author":"Catherinot","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"9526","key":"10.1002\/14651858.CD016039-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/S0140-6736(06)68851-X","article-title":"Adult cystic fibrosis presenting with recurrent non-tuberculous mycobacterial infections","volume":"367","author":"Chbeir","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ppul.21222","article-title":"Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up","volume":"45","author":"Colin","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/j.jcf.2019.04.017","article-title":"Use of inhaled imipenem\/cilastatin in pediatric patients with cystic fibrosis: A case series","volume":"18","author":"Jones","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0103|cit103","first-page":"800","article-title":"[Infections with atypical mycobacteria in children]","volume":"123","author":"Heier","year":"2003","journal-title":"Tidsskrift for Den Norske Laegeforening"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD016039-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"S773","DOI":"10.1093\/ofid\/ofz360.1938","article-title":"Clofazimine safety and efficacy for treatment of multidrug-resistant non-tuberculous mycobacteria (NTM)","volume":"6","author":"Alameer","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jcf.2021.08.010","article-title":"Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis","volume":"21","author":"Cameron","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD016039-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/INF.0000000000002274","article-title":"Improved clinical outcome after treatment of Mycobacterium abscessus complex pulmonary disease in children with cystic fibrosis","volume":"38","author":"Chacko","year":"2019","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD016039-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ppul.24152","article-title":"Clofazimine use in pediatric cystic fibrosis patients with nontuberculous mycobacteria","volume":"53","author":"Green","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD016039-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1569-1993(17)30479-4","article-title":"Tolerability of nebulised non-liposomal amikacin for the treatment of Mycobacterium abscessus infection in adults with cystic fibrosis","volume":"16","author":"Hough","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcf.2014.07.004","article-title":"Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients","volume":"14","author":"Roux","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD016039-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S1569-1993(15)30227-7","article-title":"A prospective study on non-tuberculous mycobacteria (NTM) in patients with CF","volume":"14","author":"Schwarz","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD016039-BIB0111|cit111","first-page":"A2653","article-title":"Open-label trial of amikacin liposome inhalation suspension in M. abscessus lung disease","volume":"199","author":"Siegel","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016039-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.chest.2023.05.036","article-title":"Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease","volume":"164","author":"Siegel","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/ijmy.ijmy_55_18","article-title":"Mycobacterium abscessus complex: natural history and treatment outcomes at a tertiary adult cystic fibrosis center","volume":"7","author":"Tippett","year":"2018","journal-title":"International Journal of Mycobacteriology"},{"issue":"3","key":"10.1002\/14651858.CD016039-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/thx.53.3.182","article-title":"Non-tuberculous mycobacteria in cystic fibrosis","volume":"53","author":"Torrens","year":"1998","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD016039-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","article-title":"Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens","volume":"15","author":"Cogen","year":"2018","journal-title":"Annals of the American Thoracic Society"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jcf.2015.02.006","article-title":"Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin","volume":"14","author":"Coolen","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-024-01007-8","article-title":"Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus","volume":"31","author":"Casanova","year":"2024","journal-title":"Journal of Biomedical Science"},{"issue":"10","key":"10.1002\/14651858.CD016039-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ebiom.2015.08.018","article-title":"Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum","volume":"2","author":"Devereux","year":"2015","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1002\/14651858.CD016039-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"e0067324","DOI":"10.1128\/aac.00673-24","article-title":"Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains","volume":"68","author":"Le Run","year":"2024","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"8","key":"10.1002\/14651858.CD016039-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1089\/mdr.2017.0286","article-title":"Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis","volume":"24","author":"Schwartz","year":"2018","journal-title":"Microbial Drug Resistance (Larchmont, N.Y.)"},{"issue":"Supplement","key":"10.1002\/14651858.CD016039-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.4103\/ijmy.ijmy_77_24","article-title":"Assessment of antibiotic resistance of non-tuberculosis Mycobacteria, involved in the respiratory complications of cystic fibrosis","volume":"13","author":"Vladimirovich","year":"2024","journal-title":"International Journal of Mycobacteriology"},{"issue":"2","key":"10.1002\/14651858.CD016039-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1034\/j.1399-3003.1999.14b18.x","article-title":"Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease","volume":"14","author":"Gilljam","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD016039-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"A4842","DOI":"10.1164\/ajrccm-conference.2017.B108","article-title":"Pharmacokinetics of oral mac antibiotics in cystic fibrosis","volume":"195","author":"Martiniano","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jcf.2021.04.011","article-title":"Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis","volume":"20","author":"Martiniano","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD016039-BIB0125|cit125","unstructured":"Improving treatment of nontuberculous mycobacterial infection in cystic fibrosis clinicaltrials.gov\/show\/NCT02372383"},{"issue":"3","key":"10.1002\/14651858.CD016039-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jcf.2020.09.004","article-title":"Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy","volume":"20","author":"Richter","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD016039-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"533","DOI":"10.5863\/1551-6776-26.5.517","article-title":"Therapeutic drug monitoring for mycobacterium avium complex treatment in pediatric cystic fibrosis patients","volume":"26","author":"Witcraft","year":"2021","journal-title":"Journal of Pediatric Pharmacology and Therapeutics"},{"issue":"Supplement 64","key":"10.1002\/14651858.CD016039-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2020.4344","article-title":"A first look at the Italian Registry on pulmonary non-tuberculous mycobacteria (NTM) - IRENE","volume":"56","author":"Aliberti","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD016039-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1164\/rccm.201307-1200OC","article-title":"Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis","volume":"188","author":"Binder","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD016039-BIB0130|cit130","unstructured":"Finding the optimal regimen for mycobacterium abscessus treatment (FORMAT) trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12618001831279"},{"key":"10.1002\/14651858.CD016039-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/S1569-1993(24)00393-X","article-title":"FORMaT: finding the Optimal Regimen for Mycobacterium abscessus Treatment. A randomised, multi-arm, adaptive platform trial","volume":"23","author":"Adetayo","year":"2024","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD016039-BIB0132|cit132","unstructured":"Finding the optimal regimen for mycobacterium abscessus treatment (format) classic.clinicaltrials.gov\/ct2\/show\/NCT04310930"},{"issue":"Supplement 47","key":"10.1002\/14651858.CD016039-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/ppul.23840","article-title":"Prospective algorithm for treatment of nontuberculous mycobacteria in cystic fibrosis (patience) trial: 2014-present","volume":"52","author":"Nick","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD016039-BIB0134|cit134","unstructured":"Prospective algorithm for treatment of nontuberculous mycobacteria in cystic fibrosis (patience) trial: 2014-present https:\/\/clinicaltrials.gov\/study\/NCT02419989"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0135|cit135","first-page":"A6095","article-title":"Efficient mycobacterium avium killing by human neutrophils requires opsonization","volume":"201","author":"Lenhart-Pendergrass","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016039-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"e0327922","DOI":"10.1128\/spectrum.03279-22","article-title":"Deficient complement opsonization impairs mycobacterium avium killing by neutrophils in cystic fibrosis","volume":"11","author":"Lenhart-Pendergrass","year":"2023","journal-title":"Microbiology Spectrum"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:31:36Z","timestamp":1791570696000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016039"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":136,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016039","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}